Skip to main content
Premium Trial:

Request an Annual Quote

Cadus Sells $5 Million Of Stock to SmithKline

Premium

TARRYTOWN, NY--Cadus Pharmaceuticals, a biotech company here engaged in discovery of small-molecule therapeutics, announced that it exercised an option acquired through its functional genomics collaboration with SmithKline Beecham in 1997 to sell $5 million of its common stock to the bigger pharmaceutical company. SmithKline purchased 660,962 shares of Cadus common stock at a approximately $7.56 per share. Cadus now has $42.5 million in cash and cash equivalents. Cadus develops proprietary technologies that exploit the similarities between yeast and human genomes to create drug discovery tools and to elucidate gene function and cell signaling pathways.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.